

## REQUEST FOR RECONSIDERATION

The amendments to the specification correct typographical errors; the application is uniquely identified by its filing date, title, and status as a continuation-in-part of U.S. Patent 6,156,576. The amendment to claims 66, 68, 72, 78, 86-90, 99 and 100 is supported by the specification, page 17, lines 12-20. Claim 71 has been clarified, and claim 101 has been cancelled. No new matter has been added. Upon entry of this amendment, claims 66-100 are present in the application.

Applicants would like to thank Examiner Ly and his supervisor for the courteous and helpful telephone discussion held with applicants' representative on May 9, 2005. During this discussion, applicants' representative suggested replacing the word "proteins" with the word "enzymes" in order to overcome a variety of issues, including rejections over prior art. It was agreed that such a change would assist in advancing prosecution of the application.

The challenge to examine signaling networks and other intricate webs of cellular activity, requires devising powerful techniques that permit not only analyzing these complex interactions, but also enables accurate interpretation of the resulting data. Studying one molecule at a time (the classic "reductionist" approach), has been a powerful tool, but does not efficiently unravel complex signaling pathways. The presently claimed invention meets this challenge.

The claimed invention provides methods that permit simultaneous analysis of the activities of a plurality of different enzymes. As needed, the scientist can also compile the activities of multiple enzymes, under a barrage of conditions, from which maps of cellular activity may be drawn.

The rejection of the claims under 35 U.S.C. § 103 over Day et al., Sims et al. and Wright is respectfully traversed. The references fail to suggest detecting the activities of a plurality of different enzymes in a cell.

Day et al. introduce a luciferase-green fluorescent protein chimeric protein into cells. Sims et al. teach the injection of labeled inositol phosphate into cells. Wright teaches the separation and purification of antigens specific for benign prostate hyperplasia to make antibodies. None of the references suggest detecting the activities of a plurality of different enzymes in a cell. Accordingly, applicants submit that the

claimed invention is not obvious over the applied references. Withdrawal of this ground of rejection is respectfully requested.


The rejection of the claims under 35 U.S.C. § 112, second paragraph, has been obviated by appropriate amendment, and the cancellation of claim 101. Withdrawal of this ground of rejection is respectfully requested.

The rejection of the claims under 35 U.S.C. § 112, first paragraph, has been obviated by appropriate amendment. Claims have been amended to replace "proteins" with "enzymes". Claim 71 has been amended to delete "small molecule" and "nucleic acid". Claim 101 has been cancelled. Finally, applicants note that the phrase "at most" is the logical equivalent of "less than or equal to". Withdrawal of this ground of rejection is respectfully requested.

Applicants respectfully traverse the conclusion of lack of entitlement to priority from provisional application 60/252,861. Priority must be determined on a claim-by-claim basis, based on the current (as amended) language of the claims. However, the amendments to the claims render this issue moot.

Applicants provide herewith a Supplemental Application Data Sheet, updating application information.

Respectfully submitted,



Paul E. Rauch, Ph.D.  
Registration No. 38,591

Evan Law Group LLC  
566 West Adams  
Suite 350  
Chicago, Illinois 60661  
(312) 876-1400